Skip to content
Industrial Relations, Medical Health Aged Care

Study raises concern about opioid prescribing to injured Australian workers

Monash University 2 mins read

Thousands of injured Victorian employees are receiving high-risk opioid prescriptions, Monash University-led research has found.

 

Published in the peer-reviewed journal CNS Drugs, the study investigated opioid prescriptions for injured employees funded by the Victorian workers’ compensation system, and for the first time measured the number with early high-risk prescribing patterns.

 

Researchers analysed data from 30,590 employees with back and neck injuries from 2010 to 2019, who had time off work due to their injury and made a workers’ compensation claim. Of these, 6,278 (about 20.5 per cent) were prescribed opioids in the first three months of their claim.

 

It is generally recommended to avoid opioids if possible and use other pain relief methods first. If opioids are prescribed, they should be used for a short time and in low doses.  


Among those prescribed opioids in the first three months, two out of three workers (67.1 per cent) had early high-risk opioid prescriptions, and nearly one in four (22.8 per cent) continued using opioids after a year.

 

“We analysed detailed data on the type, volume and timing of opioid prescriptions paid for by the workers’ compensation system,” said first author Yonas Tefera, from Monash University’s School of Public Health and Preventive Medicine Healthy Working Lives Research Group.

 

“Prescribing was considered high-risk if there was a large volume prescribed within the first three months, if long-acting opioids were prescribed early, or if other high-risk medicines were prescribed at the same time as opioids.

 

“We also found that early high-risk prescribing doubled the chances of long-term opioid use. Previous studies show that injured workers who use opioids early or for a long time tend to have more time off work and worse health outcomes.”


The study also found that workers in rural and more economically disadvantaged areas were more likely to receive early high-risk opioid prescriptions and also to have long term use.

 

Senior author and Healthy Working Lives Research Group Director Professor Alex Collie said the results highlighted the extent of two potentially very harmful patterns among workers with common workplace injuries and compensation claims – early high-risk opioid prescribing and long-term opioid use.

 

“More than 120,000 Australians have workers compensation claims involving more than a week off work every year, and many of these claims are for back and neck injuries,” Professor Collie said.

 

“If the patterns we observe in Victoria also occur in other states and territories, then potentially thousands of workers are receiving high-risk opioid prescriptions funded by our workers compensation systems.

 

“This study highlights the need for stronger monitoring of prescription patterns in our workers’ compensation systems, and the need for stronger approaches to prevent potentially harmful prescription opioid use.

 

In another study published last year in the Journal of Occupational and Environmental Medicine, the Monash research team found that most workers’ compensation regulators in Australia do not routinely capture data on prescription medicines.

 

“Victoria is one of only two states in the country where this sort of analysis is possible, because the other state workers’ compensation systems aren’t collecting detailed information on the medicines they are paying for,” Professor Collie said. 

 

For media enquiries please contact:

 

Monash University

Cheryl Critchley – Media and Communications Manager (medical)
E:
[email protected]

T: +61 (0) 477 571 442

 

For more Monash media stories, visit our news and events site 


For general media enquiries please contact:
Monash Media
E: 
[email protected]
T: +61 (0) 3 9903 4840

 

***ENDS***

More from this category

  • Medical Health Aged Care
  • 16/12/2025
  • 12:11
Esco Aster Pte. Ltd.

Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform

SINGAPORE–BUSINESS WIRE– Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G…

  • Contains:
  • Medical Health Aged Care
  • 16/12/2025
  • 11:30
Dementia Australia

Dementia Australia pays tribute to Patron Allan Moffat OBE

Dementia Australia solemnly acknowledges the Victorian State Memorial Service to honour and celebrate Allan Moffat OBE to be held today at Melbourne Town Hall. Mr Moffat, the Motorsport racing legend died from Alzheimer’s disease on 22 November and was a Patron of Dementia Australia following his decision to speak out publicly about his diagnosis to help raise funds and awareness of dementia. Dementia Australia acknowledges the condolences and support from The Hon. Jacinta Allan MP, Premier of Victoria, the Victorian State Government and Australian Federal Government in remembering Allan’s extraordinary career and dementia advocacy. Dementia Australia extends thanks to the…

  • Government Federal, Medical Health Aged Care
  • 16/12/2025
  • 11:27
Australian College of Nursing

ACN urges community healing in wake of the Bondi tragedy

Addressing the General Meeting of the Australian College of Nursing (ACN) Board in Canberra today, ACN President Kath Stein FACN offered condolences to all victims of the tragic terror event at Bondi Beach on Sunday evening. Ms Stein said Australia’s nurses support the families of all those affected by the shooting and its aftermath and stand with Australia’s Jewish community during this period of grieving and recovery. “On behalf of theACN Board and our members, I praise the nurses and their colleagues who are working around the clock caring for the innocent victims and the first responders who were injured…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.